Dir
James Zuie-chin Huang, M.B.A., is a seasoned biotechnology executive with over 30 years of experience as an entrepreneur, investor, and key opinion leader in the healthcare sector.[[1]](https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html)[[2]](https://www.biospace.com/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors) He is the Founder and Managing Partner of Panacea Venture, a significant shareholder of Connect Biopharma Holdings Limited (Nasdaq: CNTB), and serves as a Director on its Board, appointed effective February 12, 2024.[[1]](https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html)[[2]](https://www.biospace.com/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors)[[4]](https://www.gurufocus.com/news/8766068/connect-biopharma-cntb-sees-directors-major-stock-purchase)[[5]](https://www.sec.gov/Archives/edgar/data/1835268/000183526824000004/connectform6-kjanuary2024j.htm)[[6]](https://www.connectbiopharma.com/board-of-directors) In this role, Huang contributes his deep industry insights to advance the company's pipeline, including rademikibart for atopic dermatitis and asthma.[[1]](https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html)[[2]](https://www.biospace.com/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors)
Huang's career highlights include prior roles as Managing Partner at Kleiner Perkins China (focusing on life sciences) and Vivo Ventures (leading China investments), President of Anesiva (a pain-management biopharma), and senior positions in business development, sales, marketing, and R&D at Tularik Inc. (acquired by Amgen), GlaxoSmithKline, Bristol-Myers Squibb, and ALZA Corp. (acquired by Johnson & Johnson).[[1]](https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html)[[2]](https://www.biospace.com/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors) He currently serves on the boards of companies such as Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, and others.[[1]](https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html)[[2]](https://www.biospace.com/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors) Huang holds an M.B.A. from the Stanford Graduate School of Business and a B.S. in chemical engineering from the University of California, Berkeley.[[1]](https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html)[[2]](https://www.biospace.com/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors) Recently, as a director, he purchased 1.16 million shares of CNTB on March 31 for $4 million, signaling confidence in the company.[[4]](https://www.gurufocus.com/news/8766068/connect-biopharma-cntb-sees-directors-major-stock-purchase)
View full insider profile →
